Key Insights

Highlights

Treatment Research

1 treatments under study, led by Tapentadol Hydrochloride

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01631513Phase 4Withdrawn

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

Showing all 1 trials

Research Network

Common Treatments

  • Tapentadol Hydrochloride1

Active Sponsors

  • Janssen Scientific Affairs, LLC1

Related Conditions

  • Chronic Back Pain1
  • Chronic Low Back Pain1
  • Pain1

Activity Timeline